Hagens Berman Investigating Myriad Genetics (MYGN) For Possible Disclosure Violations, Investors With Losses Should Contact Firm

SAN FRANCISCO, Aug. 19, 2019 /PRNewswire/ -- Hagens Berman notifies investors in Myriad Genetics, Inc. (NASDAQ: MYGN) of the firm's investigation of possible disclosure violations concerning its GeneSight® Psychotropic test, one of Myriad's most important products. If you invested in...

from PR Newswire: https://ift.tt/31NHNtL